The United States of America, As Represented by the Secretary, Department of Health and Human Services

The University of Birmingham

University of Connecticut

Baylor College of Medicine

Masaki Terabe

Jay A Berzofsky

Gurdyal S Besra

Jessica J O'Konek

Petr Illarionov

Ira H Pastan

Yi-Hsiang Huang

Lauren V Wood

Brenda D Roberson

Stewart K Richardson

Malcolm K Brenner

Amy R Howell

Jason C Steel

John C Morris

Lise H Pasquet

Kaddy Camara

Petr A Illarionov

So Matsui

Disclosed is a compound of the formula (I) or (II): wherein a f are as described herein. The compounds are useful in the activation of Type II NKT cells and in treating cancer.

3-o-sulfo-galactosylceramide analogs as activators of type II NKT cells and uses thereof

Recombinant adenoviruses expressing the extracellular (EC) and transmembrane (TM) domains of human HER2 (HER2ECTM) are described. The recombinant adenoviruses express a chimeric fiber protein having the adenovirus type 35 (Ad5) shaft and knob domains, which facilitates transduction of human dendritic cells by the recombinant HER2ECTM expressing adenovirus. Compositions that include dendritic cells transduced by the recombinant adenovirus and their use for treating HER-positive tumors is described.

Compositions and methods for the treatment of HER2-expressing solid tumors

Immunogenic T cell receptor &#x3b3; alternate reading frame protein (TARP) peptide compositions that include multiple epitopes of the TARP protein are described. The disclosed compositions can be used for the treatment of TARP-expressing cancers, such as prostate cancer, breast cancer and mesothelioma. In some embodiments, the TARP peptide compositions disclosed herein include sets of overlapping TARP peptides that each have a length of about 15 to about 25 amino acids, and comprise about 5 to about 15 amino acids that are identical to at least another overlapping peptide in the set. In particular examples, the combination of the overlapping TARP peptides in the set encompasses the complete amino acid sequence of human TARP. The multi-epitope peptide compositions described herein include both CD4 and CD8 epitopes, a feature that is important for eliciting CD4T cell and CD8T cell, as well as humoral, immune responses.

Multi-epitope TARP peptide vaccine and uses thereof

&#x3b2;-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of &#x3b1;-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising &#x3b2;-mannosylceramide, as well as methods of treatment of tumors are also provided.

Beta-mannosylceramide and stimulation of NKT cell anti-tumor immunity

POTE has recently been identified as a tumor antigen expressed in a variety of human cancers, including colon, ovarian, breast, prostate, lung and pancreatic cancer. Described herein are immunogenic POTE polypeptides, including modified POTE polypeptides, that bind MHC class I molecules. The immunogenic POTE polypeptides are capable of inducing an immune response against POTE-expressing tumor cells. Thus, provided herein is a method of eliciting an immune response in a subject, such as a subject having a type of cancer that expresses POTE.

Immunogenic POTE peptides and methods of use

&#x3b2;-mannosylceramide and stimulation of NKT cell anti-tumor immunity

Growing community of inventors

Potomac, MD, United States of America

Masaki Terabe